Krystal Biotech (KRYS) Enterprise Value (2016 - 2026)

Krystal Biotech has disclosed Enterprise Value across 11 years of filings, most recently posting -$823.4 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$823.4 million, down 33.49% year-over-year; the trailing twelve-month figure through Mar 2026 was -$823.4 million (down 33.49% YoY), and the FY2025 annual result was -$827.8 million, down 38.54% from the prior year.
• Enterprise Value came in at -$823.4 million for Q1 2026 at Krystal Biotech, up from -$827.8 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$350.4 million in Q1 2023 to a low of -$827.8 million in Q4 2025.
• The 5-year median for Enterprise Value is -$559.6 million (2024), against an average of -$560.0 million.
• Across the five-year window, Enterprise Value increased 19.38% in 2023 and plunged 53.62% in 2024, its largest moves.
• Krystal Biotech's Enterprise Value stood at -$379.2 million in 2022, then plunged by 40.35% to -$532.2 million in 2023, then declined by 12.28% to -$597.5 million in 2024, then plunged by 38.54% to -$827.8 million in 2025, then grew by 0.53% to -$823.4 million in 2026.
• The last three Enterprise Value figures came in at -$823.4 million (Q1 2026), -$827.8 million (Q4 2025), and -$731.1 million (Q3 2025), per Business Quant data.